Financial Data and Key Metrics Changes - The company reported net investment income (NII) of $16.6 million or $0.45 per share for Q1 2025, down from $20.5 million or $0.55 per share in Q4 2024, primarily due to lower base rates, the roll-off of one-time items, and reduced dividend income from the Logan JV [5][23][24] - The increase in loans on non-accrual rose to 3.5% of debt investments at cost and fair value, with four new names added, representing less than 1.2% of the total portfolio at fair value [6][12] Business Line Data and Key Metrics Changes - Gross deployment in Q1 totaled $105 million, with 98% in first lien investments, compared to approximately $78 million in exits, resulting in a net deployment of approximately $27 million [17] - The weighted average yield of income-producing securities at cost decreased by 50 basis points quarter over quarter to 10.4% [20] Market Data and Key Metrics Changes - The company noted a slowdown in M&A activity due to tariff announcements, leading to a backlog of deal activity [8] - The overall direct material exposure of the portfolio to tariffs is modest at 4%, with a focus on service businesses with low material costs [18] Company Strategy and Development Direction - The company continues to focus on first lien loans, which represent 91% of the portfolio at fair value, and aims to invest in non-cyclical industries [11] - The management emphasized a disciplined credit underwriting approach and capital preservation, particularly in light of market volatility [30] Management's Comments on Operating Environment and Future Outlook - Management expressed that the current earnings reflect a near-term baseline, with potential tailwinds from asset-based facility repricing and rightsizing completed at the beginning of the quarter [6][7] - The company remains optimistic about its ability to weather potential volatility due to its diversified portfolio and strong relationships with private equity sponsors [20] Other Important Information - The company declared a regular dividend of $0.42 per share for Q2 2025, along with a special dividend related to undistributed taxable income [12][29] - The stockholders' equity was reported at $727 million, resulting in a net asset value per share of $19.62 [26] Q&A Session Summary Question: Regarding the new accruals this quarter, specifically New Era of Technology - Management clarified that the mark reflects the latest view on earnings outlook and that the company has not yet restructured [34][36] Question: What is Crescent's approach to resolving non-accrual situations? - Management stated that the primary goal is to preserve capital, and they consider various options including restructuring or selling the company [42][44] Question: Can you explain the significant decline in the Logan dividend? - Management explained that the decline was due to timing mismatches in cash distributions and the impact of overcollateralization tests within the CLO structure [50][56] Question: What percentage of the portfolio consists of Crescent-led deals? - Management indicated that about 8% of the total fair value consists of acquired assets, while 92% are loans originated by Crescent [46] Question: What is the sentiment towards the overall market and outlook for spreads? - Management noted significant inflows into non-traded BDCs, which are putting pressure on spreads, but they remain selective in their investment approach [78][82]

Financial Data and Key Metrics Changes - The company reported net investment income (NII) of $16.6 million or $0.45 per share for Q1 2025, down from $20.5 million or $0.55 per share in Q4 2024, primarily due to lower base rates, the roll-off of one-time items, and reduced dividend income from the Logan JV [5][23][24] - The weighted average yield of income-producing securities at cost decreased by 50 basis points quarter over quarter to 10.4% [20] - GAAP earnings per share for Q1 2025 was $0.11, with stockholders' equity at $727 million, resulting in a net asset value (NAV) per share of $19.62 [26] Business Line Data and Key Metrics Changes - Gross deployment in Q1 totaled $105 million, with 98% in first lien investments, compared to approximately $78 million in exits, resulting in a net deployment of approximately $27 million [16][17] - The investment portfolio consists primarily of first lien loans, representing 91% of the portfolio at fair value, with a focus on non-cyclical industries [11] Market Data and Key Metrics Changes - The company noted a slowdown in M&A activity due to tariff announcements, leading to a wait-and-see approach from sponsors [7] - The overall direct material exposure of the portfolio to tariffs is modest at 4%, with most businesses serving domestic markets [18] Company Strategy and Development Direction - The company emphasizes a disciplined credit underwriting approach, capital preservation, and strong free cash flow generation to navigate market volatility [30] - The focus remains on high-quality assets and maintaining a stable NAV rather than chasing yield [82] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about the market, noting that while there are attractive investment opportunities, the recent tariff announcements have created uncertainty [8][78] - The company anticipates potential near-term tailwinds from asset-based facility repricing and rightsizing completed at the beginning of the quarter [6] Other Important Information - The company declared a regular dividend of $0.42 per share for Q2 2025, along with a special dividend related to undistributed taxable income [12][29] - The weighted average loan-to-value across investments is 39%, indicating a conservative approach to leverage [11] Q&A Session Summary Question: Regarding the new accruals this quarter, does it reflect the restructuring recently announced for that company? - Management clarified that the company has not yet restructured and that the mark reflects the latest view on earnings outlook [34][37] Question: What is Crescent's overall approach to working toward a resolution for non-accruals? - The company prioritizes capital preservation and may consider various options, including restructuring or selling the company, depending on the situation [42][43] Question: How much of the portfolio consists of Crescent-led or originated deals? - Approximately 8% of the total fair value consists of acquired assets, while 92% are loans originated by Crescent [45] Question: Can you explain the significant sequential decline in the Logan dividend? - Management explained that the decline was due to timing mismatches in cash flows and the nature of the equity tranche, which can be volatile during the deleveraging period [48][54] Question: Were there any warning signs for the new non-accruals? - Management indicated that the non-accruals were previously on the watch list, and developments at the respective borrowers warranted the classification [59]

Lightwave Logic (LWLG) FY 2025 Annual General Meeting May 15, 2025 12:00 PM ET Speaker0 Good morning, ladies and gentlemen. My name is Ron Bookie. I'm Chairman of the Board of LightwaveLogic. And it's my pleasure to welcome you to the company's twenty twenty five Annual Meeting of Shareholders. This meeting is also being webcast live. And the webcast will be posted on our website for a period of time after the meeting. Welcome to those shareholders participating by webcast and also welcome everybody and tha ...

Financial Data and Key Metrics Changes - For Q1 2025, total revenue increased by 17% to $6.1 million compared to $5.2 million in Q1 2024 [16] - Adjusted EBITDA for Q1 2025 was $949,000, down from $1.75 million in Q1 2024 due to lower procedure volume [7][20] - Net loss for Q1 2025 was $625,000 or $0.10 per diluted share, compared to net income of $119,000 or $0.02 per diluted share in Q1 2024 [20] Business Line Data and Key Metrics Changes - Revenue from the Direct Patient Services segment was $3.1 million for Q1 2025, a 224% increase from $963,000 in Q1 2024, driven by the Rhode Island acquisition and operations in Puebla, Mexico [16][17] - Revenue from the equipment leasing segment decreased to $3 million from $4.3 million in Q1 2024 [17] - Gamma Knife revenue declined by 18% to $2.1 million, with a 24% decrease in procedures [18] - Proton Beam Radiation Therapy revenue decreased by 38% to $1.6 million, with a 35% decrease in treatment fractions [18] Market Data and Key Metrics Changes - The company has established Gamma Knife centers in Peru and Ecuador, with a new center in Puebla, Mexico, enhancing its international presence [12] - The Rhode Island acquisition represents a significant expansion in the U.S. market, with plans for a fourth radiation therapy center and the first proton beam facility in the state [13][14] Company Strategy and Development Direction - The company is transitioning from a cancer treatment equipment leasing focus to a more patient-centric service model, aiming for long-term profitable growth [6][8] - The acquisition of Rhode Island centers and international expansion are key components of the growth strategy [10][12] - Upcoming projects include a new center in Rhode Island and a joint venture for a Gamma Knife center in Guadalajara, Mexico, which is expected to generate revenue by the end of the year [12][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth potential despite short-term fluctuations in treatment volumes [15][28] - The company is optimistic about the impact of staffing strategies and upgraded technology on future treatment volumes and profitability [11][15] - Management does not foresee significant risks from potential changes in Medicaid reimbursement rates, as most revenue comes from private insurers and Medicare [23][24] Other Important Information - The company maintains a strong balance sheet with cash and cash equivalents of $11.5 million as of March 31, 2025 [20] - Shareholders' equity was $24.7 million, reflecting a slight decrease from the previous quarter [20] Q&A Session Summary Question: Impact of lower procedure numbers and potential regulatory changes - Management indicated that changes in Medicaid reimbursement are not expected to significantly impact the company, as most revenue is derived from private insurers and Medicare [23][24] Question: Flexibility in managing fixed costs with new center openings - Management confirmed that expanding the Direct Patient Services segment will provide more control over activities and patient growth, enhancing fixed cost absorption [25]

Capital Southwest (CSWC) Q4 2025 Earnings Call May 15, 2025 11:00 AM ET Company Participants Amy Baker - EVP - AccountingMichael Sarner - President & CEOJosh Weinstein - Senior MD & Chief Investment OfficerChris Rehberger - CFO, Treasure & SecretaryMickey Schleien - MD - Equity ResearchErik Zwick - Managing Director, Equity ResearchRobert Dodd - Director - Finance Conference Call Participants Cory Johnson - Associate Analyst Operator Thank you for joining today's Capital Southwest Fourth Quarter Fiscal Year ...

Star Bulk Carriers (SBLK) Q1 2025 Earnings Call May 15, 2025 11:00 AM ET Company Participants Christos Begleris - Co-CFONicos Rescos - Chief Operating OfficerCharis Plakantonaki - Chief Strategy OfficerPetros Pappas - CEO & DirectorOmar Nokta - Managing DirectorDouglas Smith - Chairman Conference Call Participants Christopher Robertson - Equity Research Analyst - Vice President Operator Thank you for standing by, ladies and gentlemen, and welcome to the Star Bulk Carriers Conference Call on the First Quarte ...

Capital Southwest (CSWC) Q4 2025 Earnings Call May 15, 2025 11:00 AM ET Company Participants Amy Baker - EVP - AccountingMichael Sarner - President & CEOJosh Weinstein - Senior MD & Chief Investment OfficerChris Rehberger - CFO, Treasure & SecretaryMickey Schleien - MD - Equity ResearchErik Zwick - Managing Director, Equity ResearchRobert Dodd - Director - Finance Conference Call Participants Cory Johnson - Associate Analyst Operator Thank you for joining today's Capital Southwest Fourth Quarter Fiscal Year ...

Nauticus Robotics (KITT) Q1 2025 Earnings Call May 15, 2025 11:00 AM ET Company Participants Kristin Moorman - VP - Corporate Development & AdministrationJohn Gibson - President & CEOVictoria Hay - Principal Accounting Officer & Interim CFODaniel Dehart - VP - Field OperationsSteve Walsh - VP - SalesJason Close - VP - Autonomous Software SolutionsAmeen Albadri - VP - Hardware EngineeringKunal Madhukar - Managing Director Conference Call Participants None - Analyst Operator Good day, ladies and gentlemen, an ...

Data Storage (DTST) Q1 2025 Earnings Call May 15, 2025 11:00 AM ET Company Participants Alexandra Schilt - Vice PresidentCharles Piluso - Chairman, CEO & TreasurerChris Panagiotakos - Chief Financial OfficerAdam Waldo - Chairman & Managing Member Conference Call Participants Matthew Galinko - SVP & Senior Research Analyst Operator and welcome to the Data Storage Corporation First Quarter twenty twenty five Earnings Call. At this time, all participants are in a listen only mode. A question and answer session ...

GEE Group (JOB) Q2 2025 Earnings Call May 15, 2025 11:00 AM ET Company Participants Derek Dewan - Chairman & CEOKim Thorpe - SVP and CFO Derek Dewan Hello, and welcome to the GEE Group Fiscal twenty twenty five Second Quarter and First Half Ended 03/31/2025 Earnings and Update Webcast Conference Call. I'm Derek Dwan, Chairman and Chief Executive Officer of GEE Group. I will be hosting today's call. Joining me as a co presenter is Kim Thorpe, our Senior Vice President and Chief Financial Officer. Thank you f ...